Loading...
•
Dec 31, 2024
Relay Therapeutics Q4 2024 Earnings Report
Estimated Revenue:$5.42M
+4079.8% YoY
Estimated EPS:-$0.56
+28.1% YoY
Key Takeaways
Relay Therapeutics reported no revenue for Q4 2024. Cash, cash equivalents, and investments totaled $781.3 million. Net loss was $76.0 million, or $0.45 per share. The company anticipates initiating the Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in mid-2025.
RLY-2608 breast cancer program continued to advance, driven by positive maturation of the RLY-2608 + fulvestrant doublet dataset.
Interim data for RLY-2608 + fulvestrant showed 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- advanced breast cancer.
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer
Approximately $780 million in cash, cash equivalents and investments at end of Q4 2024, which will be prioritized to fully fund the execution of the ReDiscover-2 Phase 3 trial
Forward Guidance
Relay Therapeutics plans to advance its clinical programs, including initiating the RLY-2608 + fulvestrant Phase 3 trial in breast cancer patients and anticipates several milestones in 2025.
Positive Outlook
- Initiation of Phase 3 trial in the middle of 2025
- Additional Phase 1b doublet data in 2025
- RLY-2608 clinical trial initiation in vascular malformations is expected in the first quarter of 2025
- NRAS and Fabry programs continue to advance towards IND
- Current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2027.
Challenges Ahead
- The timing of clinical start for NRAS and Fabry programs will be phased to optimize resources to ensure the execution of the ReDiscover-2 Phase 3 trial
- Potential delays or pauses in current or planned clinical trials
- Risk that preliminary or interim results may not be predictive of future results
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...